Daily Activity After Corticosteroids Injection Among Knee Osteoarthritis Patients
Quantification of Daily Physical Activity After an Intra-articular Corticosteroid Injection in Patients With Knee Osteoarthritis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Quebec, Canada, G1V 0A6
- Pavillon de l'Éducation Physique et des Sports - Université Laval
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 50 years old or more
- Medial knee osteoarthritis (Kellgren & Lawrence Grade I to III)
Exclusion Criteria:
- Intra-articular injection during the last six months
- Isolated femoro-patellar arthritis
- Rheumatoid arthritis
- Knee instability
- Spinal stenosis
- Lower limb fracture over the last year
- Lower limb surgery in the last three months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Injection
Corticosteroids injection
|
A solution of triamcinolone 40 mg (Kenalog) mixed with 3 cc of 2% xylocaine without epinephrine.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in Knee pain
Time Frame: Change from Baseline at 2, 4 and 6 weeks
|
Change from Baseline at 2, 4 and 6 weeks
|
|
Change in physical activity
Time Frame: Change from baseline at 2, 4 and 6 weeks
|
Change from baseline at 2, 4 and 6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in function and quality of life
Time Frame: Change from baseline at 2, 4 and 6 weeks
|
Assessment with WOMAC and MOS-SF36 questionnaires
|
Change from baseline at 2, 4 and 6 weeks
|
|
Change in Spatiotemporal gait parameters
Time Frame: Change from Baseline at 2, 4 and 6 weeks
|
Gait symmetry was verified with regards to the swing and stance phase durations and step length
|
Change from Baseline at 2, 4 and 6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Étienne Belzile, MD, Laval University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- INF-2010
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.